48 Pharmaceutical Companies Lay Off Employees Amid Industry Crisis

In a startling trend, 48 pharmaceutical companies have announced workforce reductions within the first two months of 2025. This marks a significant increase compared to previous years, highlighting the growing challenges within the industry.

According to incomplete statistics from Saibolun, the number of companies implementing layoffs has surged, with February seeing a 44% increase in layoffs compared to the same period last year. In January 2023, 24 companies reported job cuts, while this year, that number has already reached 48, reflecting a concerning trajectory for the sector.

Unlike previous years, where larger multinational corporations predominated the announcements, this year’s list features a worrying trend of smaller biotech firms facing closure. Among the companies facing significant cuts, Kojin Therapeutics, a Boston-based biotech established in 2021, has announced plans to cease operations due to insufficient funding and lack of clinical progress. The company, which had raised $60 million in Series A funding, cited a variety of challenges, including dwindling investor interest in early-stage clinical trials and a lack of support from key investors.

The tightening financial landscape is affecting not just overseas firms but also domestic companies struggling with high preclinical costs and limited breakthroughs. As investment criteria shift toward clinical viability, many firms now face the harsh reality of needing to reallocate resources effectively.

This wave of layoffs and restructuring reflects a broader structural adjustment in the pharmaceutical industry. As the capital tide recedes, companies that can promptly address clinical needs will have a better chance of surviving in this increasingly competitive environment.